These findings offered valuable evidence for considering TGF-β1 as a biomarker and therapeutic target in breast cancer, highlighting the potential development of KBU2046 as a novel anticancer agent against breast cancer metastasis. This evidence concerns the gene TGFB1 and breast cancer.